Skip to main content
Top
Published in: Pediatric Nephrology 7/2011

01-07-2011 | Original Article

Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group

Authors: Claus Peter Schmitt, Sevcan A. Bakkaloglu, Günter Klaus, Cornelis Schröder, Michel Fischbach

Published in: Pediatric Nephrology | Issue 7/2011

Login to get access

Abstract

The purpose of this article is to provide recommendations on the choice of peritoneal dialysis (PD) fluids in children by the European Pediatric Dialysis Working Group. The literature on experimental and clinical studies with PD solutions in children and adults was analyzed together with consensus discussions within the group. A grading was performed based on the international KDIGO nomenclature and methods. The lowest glucose concentration possible should be used. Icodextrin may be applied once daily during the long dwell, in particular in children with insufficient ultrafiltration. Infants on PD are at risk of ultrafiltration-associated sodium depletion, while anuric adolescents may have water and salt overload. Hence, the sodium chloride balance needs to be closely monitored. In growing children, the calcium balance should be positive and dialysate calcium adapted according to individual needs. Limited clinical experience with amino acid-based PD fluids in children suggests good tolerability. The anabolic effect, however, is small; adequate enteral nutrition is preferred. CPD fluids with reduced glucose degradation products (GDP) content reduce local and systemic toxicity and should be preferred whenever possible. Correction of metabolic acidosis is superior with pH neutral bicarbonate-based fluids compared with single-chamber, acidic, lactate-based solutions. Prospective comparisons of low GDP solutions with different buffer compositions are still few, and firm recommendations cannot yet be given, except when hepatic lactate metabolism is severely compromised.
Literature
1.
go back to reference Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT (2002) Peritoneal Biopsy Study Group Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13:470–479PubMed Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT (2002) Peritoneal Biopsy Study Group Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13:470–479PubMed
2.
go back to reference Yoshino A, Honda M, Fukuda M, Araki Y, Hataya H, Sakazume S, Tanaka Y, Kawamura K, Murai T, Kamiyama Y (2001) Changes in peritoneal equilibration test values during long-term peritoneal dialysis in peritonitis-free children. Perit Dial Int 21:180–185PubMed Yoshino A, Honda M, Fukuda M, Araki Y, Hataya H, Sakazume S, Tanaka Y, Kawamura K, Murai T, Kamiyama Y (2001) Changes in peritoneal equilibration test values during long-term peritoneal dialysis in peritonitis-free children. Perit Dial Int 21:180–185PubMed
3.
go back to reference Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, Misselwitz J, Pieper AK, Schaefer F, for the Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS) (2007) Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 22:2038–2044PubMed Schmitt CP, von Heyl D, Rieger S, Arbeiter K, Bonzel KE, Fischbach M, Misselwitz J, Pieper AK, Schaefer F, for the Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS) (2007) Reduced systemic advanced glycation end products in children receiving peritoneal dialysis with low glucose degradation product content. Nephrol Dial Transplant 22:2038–2044PubMed
4.
go back to reference Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E (2003) Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63:298–305PubMed Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E (2003) Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63:298–305PubMed
5.
go back to reference Schaefer F, Klaus G, Müller-Wiefel DE, Mehls O, Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS) (1999) Current practice of peritoneal dialysis in children: results of a longitudinal survey. Perit Dial Int 19 [Suppl 2]:S445–S449PubMed Schaefer F, Klaus G, Müller-Wiefel DE, Mehls O, Mid European Pediatric Peritoneal Dialysis Study Group (MEPPS) (1999) Current practice of peritoneal dialysis in children: results of a longitudinal survey. Perit Dial Int 19 [Suppl 2]:S445–S449PubMed
6.
go back to reference Frischmann M, Spitzer J, Fünfrocken M, Mittelmaier S, Deckert M, Fichert T, Pischetsrieder M (2009) Development and validation of an HPLC method to quantify 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids. Biomed Chromatogr 23:843–851PubMed Frischmann M, Spitzer J, Fünfrocken M, Mittelmaier S, Deckert M, Fichert T, Pischetsrieder M (2009) Development and validation of an HPLC method to quantify 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids. Biomed Chromatogr 23:843–851PubMed
7.
go back to reference Erixon M, Wieslander A, Lindén T, Carlsson O, Forsbäck G, Svensson E, Jönsson JA, Kjellstrand P (2006) How to avoid glucose degradation products in peritoneal dialysis fluids. Perit Dial Int 26:490–497PubMed Erixon M, Wieslander A, Lindén T, Carlsson O, Forsbäck G, Svensson E, Jönsson JA, Kjellstrand P (2006) How to avoid glucose degradation products in peritoneal dialysis fluids. Perit Dial Int 26:490–497PubMed
8.
go back to reference Schröder CH, European Paediatric Peritoneal Dialysis Working Group (2001) The choice of dialysis solutions in pediatric chronic peritoneal dialysis: guidelines by an ad hoc European committee. Perit Dial Int 21:568–574PubMed Schröder CH, European Paediatric Peritoneal Dialysis Working Group (2001) The choice of dialysis solutions in pediatric chronic peritoneal dialysis: guidelines by an ad hoc European committee. Perit Dial Int 21:568–574PubMed
9.
go back to reference Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A, Moist L, Steinberg E, Walker R, Wanner C, Lameire N, Eknoyan G (2001) Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70:2058–2065PubMed Uhlig K, Macleod A, Craig J, Lau J, Levey AS, Levin A, Moist L, Steinberg E, Walker R, Wanner C, Lameire N, Eknoyan G (2001) Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 70:2058–2065PubMed
10.
go back to reference Davies SJ, Phillips L, Naish PF, Russell GI (2001) Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 12:1046–1051PubMed Davies SJ, Phillips L, Naish PF, Russell GI (2001) Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 12:1046–1051PubMed
11.
go back to reference Fischbach M, Desprez P, Donnars F, Hamel G, Geisert J (1994) Optimization of CCPD prescription in children using peritoneal equilibration test. Adv Perit Dial 10:307–309PubMed Fischbach M, Desprez P, Donnars F, Hamel G, Geisert J (1994) Optimization of CCPD prescription in children using peritoneal equilibration test. Adv Perit Dial 10:307–309PubMed
12.
go back to reference Hölttä T, Happonen JM, Rönnholm K, Fyhrquist F, Holmberg C (2001) Hypertension, cardiac state, and the role of volume overload during peritoneal dialysis. Pediatr Nephrol 16:324–331PubMed Hölttä T, Happonen JM, Rönnholm K, Fyhrquist F, Holmberg C (2001) Hypertension, cardiac state, and the role of volume overload during peritoneal dialysis. Pediatr Nephrol 16:324–331PubMed
13.
go back to reference Groothoff J, Gruppen M, de Groot E, Offringa M (2005) Cardiovascular disease as a late complication of end-stage renal disease in children. Perit Dial Int 25 [Suppl 3]:S123–S126PubMed Groothoff J, Gruppen M, de Groot E, Offringa M (2005) Cardiovascular disease as a late complication of end-stage renal disease in children. Perit Dial Int 25 [Suppl 3]:S123–S126PubMed
14.
go back to reference Schmitt CP, Haraldsson B, Doetschmann R, Zimmering M, Greiner C, Böswald M, Klaus G, Passlick-Deetjen J, Schaefer F (2002) Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children. Kidney Int 61:1527–1536PubMed Schmitt CP, Haraldsson B, Doetschmann R, Zimmering M, Greiner C, Böswald M, Klaus G, Passlick-Deetjen J, Schaefer F (2002) Effects of pH-neutral, bicarbonate-buffered dialysis fluid on peritoneal transport kinetics in children. Kidney Int 61:1527–1536PubMed
15.
go back to reference Witowski J, Topley N, Jorres A, Liberek T, Coles GA, Williams JD (1995) Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 47:282–293PubMed Witowski J, Topley N, Jorres A, Liberek T, Coles GA, Williams JD (1995) Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cell interleukin-6 and prostaglandin synthesis. Kidney Int 47:282–293PubMed
16.
go back to reference Breborowicz A, Rodela H, Martis L, Oreopoulos DG (1996) Intracellular glutathione in human peritoneal mesothelial cells exposed in vitro to dialysis fluid. Int J Artif Organs 19:268–275PubMed Breborowicz A, Rodela H, Martis L, Oreopoulos DG (1996) Intracellular glutathione in human peritoneal mesothelial cells exposed in vitro to dialysis fluid. Int J Artif Organs 19:268–275PubMed
17.
go back to reference Zareie M, Hekking LH, Welten AG, Driesprong BA, Schadee-Eestermans IL, Faict D, Leyssens A, Schalkwijk CG, Beelen RH, Ter Wee PM, Van Den Born J (2003) Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 18:2629–2637PubMed Zareie M, Hekking LH, Welten AG, Driesprong BA, Schadee-Eestermans IL, Faict D, Leyssens A, Schalkwijk CG, Beelen RH, Ter Wee PM, Van Den Born J (2003) Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 18:2629–2637PubMed
18.
go back to reference Plum J, Razeghi P, Lordnejad RM, Perniok A, Fleisch M, Fussholler A, Schneider M, Grabensee B (2001) Peritoneal dialysis fluids with a physiologic pH based on either lactate or bicarbonate buffer-effects on human mesothelial cells. Am J Kidney Dis 38:867–875PubMed Plum J, Razeghi P, Lordnejad RM, Perniok A, Fleisch M, Fussholler A, Schneider M, Grabensee B (2001) Peritoneal dialysis fluids with a physiologic pH based on either lactate or bicarbonate buffer-effects on human mesothelial cells. Am J Kidney Dis 38:867–875PubMed
19.
go back to reference Ogata S, Mori M, Tatsukawa Y, Kiribayashi K, Yorioka N (2006) Expression of vascular endothelial growth factor, fibroblast growth factor, and lactate dehydrogenase by human peritoneal mesothelial cells in solutions with lactate or bicarbonate or both. Adv Perit Dial 22:37–40PubMed Ogata S, Mori M, Tatsukawa Y, Kiribayashi K, Yorioka N (2006) Expression of vascular endothelial growth factor, fibroblast growth factor, and lactate dehydrogenase by human peritoneal mesothelial cells in solutions with lactate or bicarbonate or both. Adv Perit Dial 22:37–40PubMed
20.
go back to reference Thongboonkerd V, Lumlertgul D, Supajatura V (2001) Better correction of metabolic acidosis, blood pressure control, and phagocytosis with bicarbonate compared to lactate solution in acute peritoneal dialysis. Artif Organs 25:99–108PubMed Thongboonkerd V, Lumlertgul D, Supajatura V (2001) Better correction of metabolic acidosis, blood pressure control, and phagocytosis with bicarbonate compared to lactate solution in acute peritoneal dialysis. Artif Organs 25:99–108PubMed
21.
go back to reference Kierdorf HP, Leue C, Arns S (1999) Lactate- or bicarbonate-buffered solutions in continuous extracorporeal renal replacement therapies. Kidney Int Suppl 72:S32–S36 Kierdorf HP, Leue C, Arns S (1999) Lactate- or bicarbonate-buffered solutions in continuous extracorporeal renal replacement therapies. Kidney Int Suppl 72:S32–S36
22.
go back to reference Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, Pieper AK, Schaub TP, Passlick-Deetjen J, Mehls O, Schaefer F (2003) Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 14:2632–2638PubMed Haas S, Schmitt CP, Arbeiter K, Bonzel KE, Fischbach M, John U, Pieper AK, Schaub TP, Passlick-Deetjen J, Mehls O, Schaefer F (2003) Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis. J Am Soc Nephrol 14:2632–2638PubMed
23.
go back to reference Otte K, Gonzalez MT, Bajo MA, del Peso G, Heaf J, Garcia Erauzkin G, Sanchez Tomero JA, Dieperink H, Povlsen J, Hopwood AM, Divino Filho JC, Faict D (2003) Clinical experience with a new bicarbonate (25 mmol/L)/lactate (10 mmol/L) peritoneal dialysis solution. Perit Dial Int 23:138–145PubMed Otte K, Gonzalez MT, Bajo MA, del Peso G, Heaf J, Garcia Erauzkin G, Sanchez Tomero JA, Dieperink H, Povlsen J, Hopwood AM, Divino Filho JC, Faict D (2003) Clinical experience with a new bicarbonate (25 mmol/L)/lactate (10 mmol/L) peritoneal dialysis solution. Perit Dial Int 23:138–145PubMed
24.
go back to reference Feriani M, Carobi C, La Greca G, Buoncristiani U, Passlick-Deetjen J (1997) Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 17:17–21PubMed Feriani M, Carobi C, La Greca G, Buoncristiani U, Passlick-Deetjen J (1997) Clinical experience with a 39 mmol/L bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 17:17–21PubMed
25.
go back to reference Mortier S, De Vriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J, Lameire NH (2002) Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 13:480–489PubMed Mortier S, De Vriese AS, Van de Voorde J, Schaub TP, Passlick-Deetjen J, Lameire NH (2002) Hemodynamic effects of peritoneal dialysis solutions on the rat peritoneal membrane: role of acidity, buffer choice, glucose concentration, and glucose degradation products. J Am Soc Nephrol 13:480–489PubMed
26.
go back to reference Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, Wrege U, Gröntoft KC, Larsson R, Berglund J, Tranaeus AP, Faict D (1998) Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 53:1061–1067PubMed Mactier RA, Sprosen TS, Gokal R, Williams PF, Lindbergh M, Naik RB, Wrege U, Gröntoft KC, Larsson R, Berglund J, Tranaeus AP, Faict D (1998) Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 53:1061–1067PubMed
27.
go back to reference Fischbach M, Terzic J, Chauvé S, Laugel V, Muller A, Haraldsson B (2004) Effect of peritoneal dialysis fluid composition on peritoneal area available for exchange in children. Nephrol Dial Transplant 19:925–932PubMed Fischbach M, Terzic J, Chauvé S, Laugel V, Muller A, Haraldsson B (2004) Effect of peritoneal dialysis fluid composition on peritoneal area available for exchange in children. Nephrol Dial Transplant 19:925–932PubMed
28.
go back to reference Fischbach M (1996) Peritoneal dialysis prescription for neonates. Perit Dial Int 16 [Suppl 1]:512–514 Fischbach M (1996) Peritoneal dialysis prescription for neonates. Perit Dial Int 16 [Suppl 1]:512–514
29.
go back to reference Nakayama M, Kasai K, Imai H, RM-280 Study Group (2009) Novel low Na peritoneal dialysis solutions designed to optimize Na gap of effluent: kinetics of Na and water removal. Perit Dial Int 29:528–535PubMed Nakayama M, Kasai K, Imai H, RM-280 Study Group (2009) Novel low Na peritoneal dialysis solutions designed to optimize Na gap of effluent: kinetics of Na and water removal. Perit Dial Int 29:528–535PubMed
30.
go back to reference Davies S, Carlsson O, Simonsen O, Johansson AC, Venturoli D, Ledebo I, Wieslander A, Chan C, Rippe B (2009) The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status. Nephrol Dial Transplant 24:1609–1617PubMedPubMedCentral Davies S, Carlsson O, Simonsen O, Johansson AC, Venturoli D, Ledebo I, Wieslander A, Chan C, Rippe B (2009) The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status. Nephrol Dial Transplant 24:1609–1617PubMedPubMedCentral
31.
go back to reference Edefonti A, Mastrangelo A, Paglialonga F (2009) Assessment and monitoring of nutrition status in pediatric peritoneal dialysis patients. Perit Dial Int 29 [Suppl 2]:S176–S179PubMed Edefonti A, Mastrangelo A, Paglialonga F (2009) Assessment and monitoring of nutrition status in pediatric peritoneal dialysis patients. Perit Dial Int 29 [Suppl 2]:S176–S179PubMed
32.
go back to reference Wühl E, Fusch C, Schärer K, Mehls O, Schaefer F (1996) Assessment of total body water in paediatric patients on dialysis. Nephrol Dial Transplant 11(1):75–80PubMed Wühl E, Fusch C, Schärer K, Mehls O, Schaefer F (1996) Assessment of total body water in paediatric patients on dialysis. Nephrol Dial Transplant 11(1):75–80PubMed
33.
go back to reference Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, Salusky IB (2010) Value of the New Bone Classification System in Pediatric Renal Osteodystrophy. Clin J Am Soc Nephrol 5(10):1860–1866PubMedPubMedCentral Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, Salusky IB (2010) Value of the New Bone Classification System in Pediatric Renal Osteodystrophy. Clin J Am Soc Nephrol 5(10):1860–1866PubMedPubMedCentral
34.
go back to reference Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105 Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100–105
35.
go back to reference Rippe B, Levin L (1998) Should dialysate calcium be varied in proportion to the amount of ultrafiltration in peritoneal dialysis dwells? Directions from a computer simulation. Perit Dial Int 199818:474–477 Rippe B, Levin L (1998) Should dialysate calcium be varied in proportion to the amount of ultrafiltration in peritoneal dialysis dwells? Directions from a computer simulation. Perit Dial Int 199818:474–477
36.
go back to reference Eddington H, Hurst H, Ramli MT, Speake M, Hutchison AJ (2009) Calcium and magnesium flux in automated peritoneal dialysis. Perit Dial Int 29:536–541PubMed Eddington H, Hurst H, Ramli MT, Speake M, Hutchison AJ (2009) Calcium and magnesium flux in automated peritoneal dialysis. Perit Dial Int 29:536–541PubMed
37.
go back to reference Weinreich T, Passlick-Deetjen J, Ritz E, The Peritoneal Dialysis Multicenter Study Group (1995) Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. Am J Kidney Dis 25:452–460PubMed Weinreich T, Passlick-Deetjen J, Ritz E, The Peritoneal Dialysis Multicenter Study Group (1995) Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. Am J Kidney Dis 25:452–460PubMed
38.
go back to reference Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schröder C, Zurowska A, Ekim M, European Pediatric Dialysis Working Group (EPDWG) (2006) Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21:151–159 Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schröder C, Zurowska A, Ekim M, European Pediatric Dialysis Working Group (EPDWG) (2006) Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21:151–159
39.
go back to reference Ejaz AA, McShane AP, Gandhi VC, Leehey DJ, Ing TS (1995) Hypomagnesemia in continuous ambulatory peritoneal dialysis patients dialyzed with a low-magnesium peritoneal dialysis solution. Perit Dial Int 15:61–64PubMed Ejaz AA, McShane AP, Gandhi VC, Leehey DJ, Ing TS (1995) Hypomagnesemia in continuous ambulatory peritoneal dialysis patients dialyzed with a low-magnesium peritoneal dialysis solution. Perit Dial Int 15:61–64PubMed
40.
go back to reference Wei M, Esbaei K, Bargman J, Oreopoulos DG (2006) Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: a literature review. Perit Dial Int 26:366–373PubMed Wei M, Esbaei K, Bargman J, Oreopoulos DG (2006) Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: a literature review. Perit Dial Int 26:366–373PubMed
41.
go back to reference Navarro-González JF, Mora-Fernández C, García-Pérez J (2009) Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 22:37–44PubMed Navarro-González JF, Mora-Fernández C, García-Pérez J (2009) Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 22:37–44PubMed
42.
go back to reference Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jörres A (2000) Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 11:729–739PubMed Witowski J, Korybalska K, Wisniewska J, Breborowicz A, Gahl GM, Frei U, Passlick-Deetjen J, Jörres A (2000) Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 11:729–739PubMed
43.
go back to reference Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, van Ypersele de Strihou C, Kurokawa K (1999) Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 17(463):260–264 Inagi R, Miyata T, Yamamoto T, Suzuki D, Urakami K, Saito A, van Ypersele de Strihou C, Kurokawa K (1999) Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 17(463):260–264
44.
go back to reference Jonasson P, Braide M (2000) Kinetics and dose response of the effects of heated glucose peritoneal dialysis fluids on the respiratory burst of rat peritoneal leukocytes. ASAIO J 46:469–473PubMed Jonasson P, Braide M (2000) Kinetics and dose response of the effects of heated glucose peritoneal dialysis fluids on the respiratory burst of rat peritoneal leukocytes. ASAIO J 46:469–473PubMed
45.
go back to reference Witowski J, Jorres A (2009) Peritoneal dialysis: a biological membrane with a nonbiological fluid. Contrib Nephrol 163:27–34PubMed Witowski J, Jorres A (2009) Peritoneal dialysis: a biological membrane with a nonbiological fluid. Contrib Nephrol 163:27–34PubMed
46.
go back to reference Kazancioglu R (2009) Peritoneal defense mechanisms—the effects of new peritoneal dialysis solutions. Perit Dial Int 29 [Suppl 2]:S198–S201PubMed Kazancioglu R (2009) Peritoneal defense mechanisms—the effects of new peritoneal dialysis solutions. Perit Dial Int 29 [Suppl 2]:S198–S201PubMed
47.
go back to reference Shaw S, Akyol M, Bell J, Briggs JD, Dominiczak MH (1998) Effects of continuous ambulatory peritoneal dialysis and kidney transplantation on advanced glycation endproducts in the skin and peritoneum. Cell Mol Biol (Noisy-le-grand) 44:1061–1068 Shaw S, Akyol M, Bell J, Briggs JD, Dominiczak MH (1998) Effects of continuous ambulatory peritoneal dialysis and kidney transplantation on advanced glycation endproducts in the skin and peritoneum. Cell Mol Biol (Noisy-le-grand) 44:1061–1068
48.
go back to reference Han SH, Ahn SV, Yun JY, Tranaeus A, Han DS (2009) Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 54:711–720PubMed Han SH, Ahn SV, Yun JY, Tranaeus A, Han DS (2009) Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 54:711–720PubMed
49.
go back to reference Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Kim MJ, Shin SK (2006) Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 21:2893–2899PubMed Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, Kim YH, Kim YL, Kim DJ, Kim YS, Kim MJ, Shin SK (2006) Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 21:2893–2899PubMed
50.
go back to reference Topley N, Kaur D, Petersen MM, Jörres A, Passlick-Deetjen J, Coles GA, Williams JD (1996) Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int 49:1447–1456PubMed Topley N, Kaur D, Petersen MM, Jörres A, Passlick-Deetjen J, Coles GA, Williams JD (1996) Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int 49:1447–1456PubMed
51.
go back to reference Do JY, Kim YL, Park JW, Chang KA, Lee SH, Ryu DH, Kim CD, Park SH, Yoon KW (2008) The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Perit Dial Int 28 [Suppl 3]:S101–S106PubMed Do JY, Kim YL, Park JW, Chang KA, Lee SH, Ryu DH, Kim CD, Park SH, Yoon KW (2008) The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis. Perit Dial Int 28 [Suppl 3]:S101–S106PubMed
52.
go back to reference Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N (2001) Bicarbonate/Lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 21[Suppl 3]:102–107 Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N (2001) Bicarbonate/Lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 21[Suppl 3]:102–107
53.
go back to reference Mortier S, Lameire NH, De Vriese AS (2004) The effects of peritoneal dialysis solutions on peritoneal host defense. Perit Dial Int 24:123–138PubMed Mortier S, Lameire NH, De Vriese AS (2004) The effects of peritoneal dialysis solutions on peritoneal host defense. Perit Dial Int 24:123–138PubMed
54.
go back to reference Mortier S, Faict D, Gericke M, Lameire N, De Vriese A (2005) Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane. Nephron Exp Nephrol 101:e139–e145PubMed Mortier S, Faict D, Gericke M, Lameire N, De Vriese A (2005) Effects of new peritoneal dialysis solutions on leukocyte recruitment in the rat peritoneal membrane. Nephron Exp Nephrol 101:e139–e145PubMed
55.
go back to reference Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS (2004) Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 66:1257–1265PubMed Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS (2004) Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 66:1257–1265PubMed
56.
go back to reference Mortier S, Faict D, Lameire NH, De Vriese AS (2005) Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 67:1559–1665PubMed Mortier S, Faict D, Lameire NH, De Vriese AS (2005) Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model. Kidney Int 67:1559–1665PubMed
57.
go back to reference Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J, Euro Balance Trial Group (2004) The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66:408–418PubMed Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J, Euro Balance Trial Group (2004) The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 66:408–418PubMed
58.
go back to reference Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, Ahlmén J, Larsson R, Ingman B, Simonsen O, van Hamersvelt HW, Johansson AC, Hylander B, Mayr M, Nilsson PH, Andersson PO, De los Ríos T (2009) Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 29:647–55PubMed Weiss L, Stegmayr B, Malmsten G, Tejde M, Hadimeri H, Siegert CE, Ahlmén J, Larsson R, Ingman B, Simonsen O, van Hamersvelt HW, Johansson AC, Hylander B, Mayr M, Nilsson PH, Andersson PO, De los Ríos T (2009) Biocompatibility and tolerability of a purely bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 29:647–55PubMed
59.
go back to reference Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, Weiss L, Nielsen FD, Bro S, Friedberg M, Wieslander A (2001) Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59:348–357PubMed Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, Weiss L, Nielsen FD, Bro S, Friedberg M, Wieslander A (2001) Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59:348–357PubMed
60.
go back to reference Tranaeus A, The Bicarbonate/Lactate Study Group (2000) A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution—clinical benefits. Perit Dial Int 20:516–523PubMed Tranaeus A, The Bicarbonate/Lactate Study Group (2000) A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution—clinical benefits. Perit Dial Int 20:516–523PubMed
61.
go back to reference Montenegro J, Saracho RM, Martínez IM, Muñoz RI, Ocharan JJ, Valladares E (2006) Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 26:89–94PubMed Montenegro J, Saracho RM, Martínez IM, Muñoz RI, Ocharan JJ, Valladares E (2006) Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 26:89–94PubMed
62.
go back to reference Kim SG, Kim S, Hwang YH, Kim K, Oh JE, Chung W, Oh KH, Kim HJ, Ahn C, Group Korean Balnet Study (2008) Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study). Perit Dial Int 28 [Suppl 3]:S117–S122PubMed Kim SG, Kim S, Hwang YH, Kim K, Oh JE, Chung W, Oh KH, Kim HJ, Ahn C, Group Korean Balnet Study (2008) Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study). Perit Dial Int 28 [Suppl 3]:S117–S122PubMed
63.
go back to reference Haag-Weber M, Krämer R, Haake R, Islam MS, Prischl F, Haug U, Nabut JL, Deppisch R, on behalf of the DIUREST Study Group (2010) Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 25:2288–2296PubMed Haag-Weber M, Krämer R, Haake R, Islam MS, Prischl F, Haug U, Nabut JL, Deppisch R, on behalf of the DIUREST Study Group (2010) Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study. Nephrol Dial Transplant 25:2288–2296PubMed
64.
go back to reference Müller-Krebs S, Kihm LP, Zeier B, Gross ML, Deppisch R, Wieslander A, Henle T, Penndorf I, Oh J, Reiser J, Nawroth PP, Zeier M, Schwenger V (2008) Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure. Eur J Clin Invest 38:296–305PubMed Müller-Krebs S, Kihm LP, Zeier B, Gross ML, Deppisch R, Wieslander A, Henle T, Penndorf I, Oh J, Reiser J, Nawroth PP, Zeier M, Schwenger V (2008) Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure. Eur J Clin Invest 38:296–305PubMed
65.
go back to reference Ho-dac-Pannekeet MM, Weiss MF, de Waart DR, Erhard P, Hiralall JK, Krediet RT (1999) Analysis of non enzymatic glycosylation in vivo: impact of different dialysis solutions. Perit Dial Int 19 [Suppl 2]:68–74 Ho-dac-Pannekeet MM, Weiss MF, de Waart DR, Erhard P, Hiralall JK, Krediet RT (1999) Analysis of non enzymatic glycosylation in vivo: impact of different dialysis solutions. Perit Dial Int 19 [Suppl 2]:68–74
66.
go back to reference Posthuma N, ter Wee PM, Niessen H, Donker AJ, Verbrugh HA, Schalkwijk CG (2001) Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin. Perit Dial Int 21:43–51PubMed Posthuma N, ter Wee PM, Niessen H, Donker AJ, Verbrugh HA, Schalkwijk CG (2001) Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodextrin. Perit Dial Int 21:43–51PubMed
67.
go back to reference Montenegro J, Saracho R, Gallardo I, Martínez I, Muñoz R, Quintanilla N (2007) Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 22:1703–1708PubMed Montenegro J, Saracho R, Gallardo I, Martínez I, Muñoz R, Quintanilla N (2007) Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 22:1703–1708PubMed
68.
go back to reference Furkert J, Zeier M, Schwenger V (2008) Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Perit Dial Int 28(6):637–640PubMed Furkert J, Zeier M, Schwenger V (2008) Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Perit Dial Int 28(6):637–640PubMed
69.
go back to reference Moberly JB, Mujais S, Gehr T, Hamburger R, Sprague S, Kucharski A, Reynolds R, Ogrinc F, Martis L, Wolfson M (2002) Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl 81:S23–S33 Moberly JB, Mujais S, Gehr T, Hamburger R, Sprague S, Kucharski A, Reynolds R, Ogrinc F, Martis L, Wolfson M (2002) Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl 81:S23–S33
70.
go back to reference Canepa A, Verrina E, Perfumo F (2008) Use of new peritoneal dialysis solutions in children. Kidney Int Suppl 108:S137–S144 Canepa A, Verrina E, Perfumo F (2008) Use of new peritoneal dialysis solutions in children. Kidney Int Suppl 108:S137–S144
71.
go back to reference Rusthoven E, Krediet RT, Willems HL, Monnens LA, Schröder CH (2004) Peritoneal transport characteristics with glucose polymer-based dialysis fluid in children. J Am Soc Nephrol 15:2940–7PubMed Rusthoven E, Krediet RT, Willems HL, Monnens LA, Schröder CH (2004) Peritoneal transport characteristics with glucose polymer-based dialysis fluid in children. J Am Soc Nephrol 15:2940–7PubMed
72.
go back to reference Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA, The Dextrin in APD in Amsterdam (DIANA) Group (2000) Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. Perit Dial Int 20 [Suppl 2]:S106–S113PubMed Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA, The Dextrin in APD in Amsterdam (DIANA) Group (2000) Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. Perit Dial Int 20 [Suppl 2]:S106–S113PubMed
73.
go back to reference Dart A, Feber J, Wong H, Filler G (2005) Icodextrin re-absorption varies with age in children on automated peritoneal dialysis. Pediatr Nephrol 20:683–685PubMed Dart A, Feber J, Wong H, Filler G (2005) Icodextrin re-absorption varies with age in children on automated peritoneal dialysis. Pediatr Nephrol 20:683–685PubMed
74.
go back to reference Michallat AC, Dheu C, Loichot C, Danner S, Fischbach M (2005) Long daytime exchange in children on continuous cycling peritoneal dialysis: preservation of drained volume because of icodextrin use. Adv Perit Dial 21:195–199PubMed Michallat AC, Dheu C, Loichot C, Danner S, Fischbach M (2005) Long daytime exchange in children on continuous cycling peritoneal dialysis: preservation of drained volume because of icodextrin use. Adv Perit Dial 21:195–199PubMed
75.
go back to reference Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimbürger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC (2003) Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 14:2338–2344PubMed Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, Bosselmann HP, Heimbürger O, Simonsen O, Davenport A, Tranaeus A, Divino Filho JC (2003) Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 14:2338–2344PubMed
76.
go back to reference Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S (2005) Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 16:546–554PubMed Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, Nash K, Sorkin M, Mujais S (2005) Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 16:546–554PubMed
77.
go back to reference Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, Gerlag PG, Hoorntje SJ, Wolters J, van der Sande FM, Leunissen KM (2003) Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 63:1556–1563PubMed Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, Gerlag PG, Hoorntje SJ, Wolters J, van der Sande FM, Leunissen KM (2003) Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: a randomized study. Kidney Int 63:1556–1563PubMed
78.
go back to reference Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM (2000) Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 15:862–866PubMed Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM (2000) Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant 15:862–866PubMed
79.
go back to reference Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R (2001) Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 21:275–281PubMed Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R (2001) Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 21:275–281PubMed
80.
go back to reference Babazono T, Nakamoto H, Kasai K, Kuriyama S, Sugimoto T, Nakayama M, Hamada C, Furuya R, Hasegawa H, Kasahara M, Moriishi M, Tomo T, Miyazaki M, Sato M, Yorioka N, Kawaguchi Y, Japanese Extraneal Collaborated Study Group (2007) Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am J Nephrol 27:409–415PubMed Babazono T, Nakamoto H, Kasai K, Kuriyama S, Sugimoto T, Nakayama M, Hamada C, Furuya R, Hasegawa H, Kasahara M, Moriishi M, Tomo T, Miyazaki M, Sato M, Yorioka N, Kawaguchi Y, Japanese Extraneal Collaborated Study Group (2007) Effects of icodextrin on glycemic and lipid profiles in diabetic patients undergoing peritoneal dialysis. Am J Nephrol 27:409–415PubMed
81.
go back to reference Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, Macnamara E, Ekstrand A, Tranaeus A, Filho JC, EAPOS Group (2005) Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 67:1609–1615PubMed Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-Carmona A, Vychytil A, Macnamara E, Ekstrand A, Tranaeus A, Filho JC, EAPOS Group (2005) Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 67:1609–1615PubMed
82.
go back to reference Say T, Oymak O, Inanc MT, Dogan A, Tokgoz B, Utas C (2009) Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 29:443–449 Say T, Oymak O, Inanc MT, Dogan A, Tokgoz B, Utas C (2009) Effects of twice-daily icodextrin administration on blood pressure and left ventricular mass in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 29:443–449
83.
go back to reference Martis L, Patel M, Giertych J, Mongoven J, Taminne M, Perrier MA, Mendoza O, Goud N, Costigan A, Denjoy N, Verger C, Owen WF Jr (2005) Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 365:588–594PubMed Martis L, Patel M, Giertych J, Mongoven J, Taminne M, Perrier MA, Mendoza O, Goud N, Costigan A, Denjoy N, Verger C, Owen WF Jr (2005) Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 365:588–594PubMed
84.
go back to reference Adam FU, Singan M, Ozelsancak R, Torun D, Ozdemir FN, Haberal M (2007) Icodextrin-associated sterile peritonitis: a recent outbreak in Turkey. Perit Dial Int 27:598–599PubMed Adam FU, Singan M, Ozelsancak R, Torun D, Ozdemir FN, Haberal M (2007) Icodextrin-associated sterile peritonitis: a recent outbreak in Turkey. Perit Dial Int 27:598–599PubMed
85.
go back to reference Anderstam B, García-López E, Heimbürger O, Lindholm B (2003) Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid. Perit Dial Int 23:146–150PubMed Anderstam B, García-López E, Heimbürger O, Lindholm B (2003) Determination of alpha-amylase activity in serum and dialysate from patients using icodextrin-based peritoneal dialysis fluid. Perit Dial Int 23:146–150PubMed
86.
go back to reference Schalkwijk CG, ter Wee PM, Teerlink T (2000) Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids. Perit Dial Int 20:796–798PubMed Schalkwijk CG, ter Wee PM, Teerlink T (2000) Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids. Perit Dial Int 20:796–798PubMed
87.
go back to reference Bender TO, Witowski J, Aufricht C, Endemann M, Frei U, Passlick-Deetjen J, Jörres A (2008) Biocompatibility of a bicarbonate-buffered amino-acid-based solution for peritoneal dialysis. Pediatr Nephrol 23:1537–1543PubMed Bender TO, Witowski J, Aufricht C, Endemann M, Frei U, Passlick-Deetjen J, Jörres A (2008) Biocompatibility of a bicarbonate-buffered amino-acid-based solution for peritoneal dialysis. Pediatr Nephrol 23:1537–1543PubMed
88.
go back to reference Reimann D, Dachs D, Meye C, Gross P (2004) Amino acid-based peritoneal dialysis solution stimulates mesothelial nitric oxide production. Perit Dial Int 24:378–384PubMed Reimann D, Dachs D, Meye C, Gross P (2004) Amino acid-based peritoneal dialysis solution stimulates mesothelial nitric oxide production. Perit Dial Int 24:378–384PubMed
89.
go back to reference Tjiong HL, Zijlstra FJ, Rietveld T, Wattimena JL, Huijmans JG, Swart GR, Fieren MW (2007) Peritoneal protein losses and cytokine generation in automated peritoneal dialysis with combined amino acids and glucose solutions. Mediators Inflamm 2007:97272PubMedPubMedCentral Tjiong HL, Zijlstra FJ, Rietveld T, Wattimena JL, Huijmans JG, Swart GR, Fieren MW (2007) Peritoneal protein losses and cytokine generation in automated peritoneal dialysis with combined amino acids and glucose solutions. Mediators Inflamm 2007:97272PubMedPubMedCentral
90.
go back to reference Qamar IU, Secker D, Levin L, Balfe JA, Zlotkin S, Balfe JW (1999) Effects of amino acid dialysis compared to dextrose dialysis in children on continuous cycling peritoneal dialysis. Perit Dial Int 19:237–247PubMed Qamar IU, Secker D, Levin L, Balfe JA, Zlotkin S, Balfe JW (1999) Effects of amino acid dialysis compared to dextrose dialysis in children on continuous cycling peritoneal dialysis. Perit Dial Int 19:237–247PubMed
91.
go back to reference Li FK, Chan LY, Woo JC, Ho SK, Lo WK, Lai KN, Chan TM (2003) A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 42:173–183PubMed Li FK, Chan LY, Woo JC, Ho SK, Lo WK, Lai KN, Chan TM (2003) A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 42:173–183PubMed
92.
go back to reference Dombros NV, Prutis K, Tong M, Anderson GH, Harrison J, Sombolos K, Digenis G, Pettit J, Oreopoulos DG (1990) Six-month overnight intraperitoneal amino-acid infusion in continuous ambulatory peritoneal dialysis (CAPD) patients—no effect on nutritional status. Perit Dial Int 10:79–84PubMed Dombros NV, Prutis K, Tong M, Anderson GH, Harrison J, Sombolos K, Digenis G, Pettit J, Oreopoulos DG (1990) Six-month overnight intraperitoneal amino-acid infusion in continuous ambulatory peritoneal dialysis (CAPD) patients—no effect on nutritional status. Perit Dial Int 10:79–84PubMed
93.
go back to reference Tjiong HL, van den Berg JW, Wattimena JL, Rietveld T, van Dijk LJ, van der Wiel AM, van Egmond AM, Fieren MW, Swart R (2005) Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 16:1486–1493PubMed Tjiong HL, van den Berg JW, Wattimena JL, Rietveld T, van Dijk LJ, van der Wiel AM, van Egmond AM, Fieren MW, Swart R (2005) Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 16:1486–1493PubMed
94.
go back to reference Tjiong HL, Rietveld T, Wattimena JL, van den Berg JW, Kahriman D, van der Steen J, Hop WC, Swart R, Fieren MW (2007) Peritoneal dialysis with solutions containing amino acids plus glucose promotes protein synthesis during oral feeding. Clin J Am Soc Nephrol 2:74–80PubMed Tjiong HL, Rietveld T, Wattimena JL, van den Berg JW, Kahriman D, van der Steen J, Hop WC, Swart R, Fieren MW (2007) Peritoneal dialysis with solutions containing amino acids plus glucose promotes protein synthesis during oral feeding. Clin J Am Soc Nephrol 2:74–80PubMed
95.
go back to reference Vande Walle J, Raes A, Dehoorne J, Mauel R, Dejaeghere A, Matthys D (2004) Combined amino-acid and glucose peritoneal dialysis solution for children with acute renal failure. Adv Perit Dial 20:226–230 Vande Walle J, Raes A, Dehoorne J, Mauel R, Dejaeghere A, Matthys D (2004) Combined amino-acid and glucose peritoneal dialysis solution for children with acute renal failure. Adv Perit Dial 20:226–230
96.
go back to reference Brem AS, Maaz D, Shemin DG, Wolfson M (1996) Use of amino acid peritoneal dialysate for one year in a child on CCPD. Perit Dial Int 16:634–636PubMed Brem AS, Maaz D, Shemin DG, Wolfson M (1996) Use of amino acid peritoneal dialysate for one year in a child on CCPD. Perit Dial Int 16:634–636PubMed
97.
go back to reference Canepa A, Carrea A, Menoni S, Verrina E, Trivelli A, Gusmano R, Perfumo F (2001) Acute effects of simultaneous intraperitoneal infusion of glucose and amino acids. Kidney Int 59:1967–1973PubMed Canepa A, Carrea A, Menoni S, Verrina E, Trivelli A, Gusmano R, Perfumo F (2001) Acute effects of simultaneous intraperitoneal infusion of glucose and amino acids. Kidney Int 59:1967–1973PubMed
98.
go back to reference Le Poole CY, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM (2005) Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 25 [Suppl 3]:S64–S68PubMed Le Poole CY, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM (2005) Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 25 [Suppl 3]:S64–S68PubMed
99.
go back to reference Le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM (2004) Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 20:170–176PubMed Le Poole CY, van Ittersum FJ, Weijmer MC, Valentijn RM, ter Wee PM (2004) Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study. Adv Perit Dial 20:170–176PubMed
100.
go back to reference Vande Walle JG, Raes AM, Dehoorne J, Mauel R (2004) Use of bicarbonate/lactate-buffered dialysate with a nighttime cycler, associated with a daytime dwell with icodextrin, may result in alkalosis in children. Adv Perit Dial 20:222–225 Vande Walle JG, Raes AM, Dehoorne J, Mauel R (2004) Use of bicarbonate/lactate-buffered dialysate with a nighttime cycler, associated with a daytime dwell with icodextrin, may result in alkalosis in children. Adv Perit Dial 20:222–225
Metadata
Title
Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group
Authors
Claus Peter Schmitt
Sevcan A. Bakkaloglu
Günter Klaus
Cornelis Schröder
Michel Fischbach
Publication date
01-07-2011
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 7/2011
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-011-1863-4

Other articles of this Issue 7/2011

Pediatric Nephrology 7/2011 Go to the issue